Ann: Business update, page-2

Whilst I accept this message is probably somewhat of a surrender, it's a little bit cheap to blame the Covid situation for their economic woes.

CAN have tried to secure finance for their facility in prosperous economic times without success and now the convenience of Covid does lend itself as something to blame as the same situation continues.

The last statement about achieving GMP product without a guide on quantity is a little but concerning.

The fact it actually says "can now be released to the market to fill specific customer orders" is a little worrying.

It does suggest a low volume which can only be used to treat a low number of patients.

If CAN are going to continue to be a zero revenue company and not going to finish the Mildura project, then what are they actually doing?

What else is left in this business except >$300m of investors money that's been spent?